CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel treatment for age-related macular degeneration (AMD) by rejuvenating retinal pigment epithelium cells using a technique called partial reprogramming. The goal is to restore vision in patients by improving the function of damaged cells in the eye.
Age-related macular degeneration (AMD) is a leading cause for blindness, resulting in loss of vision at the center of the visual field - the macula, due to damage to the retina.
The disease, usually affecting older adults (>55), was diagnosed in 2020 in 196 million people worldwide, with an estimated economic toll of $343 billion including $255 billion in direct healthcare costs.
In AMD, photoreceptors and retinal pigmented epithelium (RPE) cells which underlie the photoreceptors undergo degener…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
